Meeting
2016 ASCO Annual Meeting
A phase 1 adaptive dose-escalation study to evaluate the tolerability, safety, pharmacokinetics, and antitumor activity of ADCT-402 in patients with relapsed or refractory B-cell lineage non Hodgkin lymphoma (BâNHL).
Authors
Ki Y. Chung
GHS Cancer Inst / ITOR, Spartanburg, SC
Ki Y. Chung , Mehdi Hamadani , Brad S. Kahl , Leonard T. Heffner , Paolo Fabrizio Caimi , Jay Marshall Feingold , Owen A. O'Connor
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Track
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Sub Track
Non-Hodgkin Lymphoma
Clinical Trial Registration Number
NCT02669017
Citation
J Clin Oncol 34, 2016 (suppl; abstr TPS7580)
DOI
10.1200/JCO.2016.34.15_suppl.TPS7580
Abstract #
TPS7580
Poster Bd #
132a
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Annual Meeting
Phase I study of CN201, a novel CD3xCD19 bispecific antibody, in patients with relapsed or refractory B-cell non-Hodgkin lymphoma.
First Author: Yang Xie
Poster
2023 ASCO Annual Meeting
A phase 1 study of AT101, a novel anti-CD19 CAR-T cell therapy targeting a membrane-proximal epitope of CD19, in patients with relapsed or refractory B cell non-Hodgkin lymphoma.
First Author: Dok Hyun Yoon
Poster
2022 ASCO Annual Meeting
Phase 1 dose escalation study of MH048, a novel and non-covalent BTK inhibitor in patients with relapsed or refractory B-cell malignancies.
First Author: Guoqing Cao
Poster
2014 ASCO Annual Meeting
Preliminary findings from a phase I, multicenter, open-label study of the anti-CD37 antibody-drug conjugate (ADC), IMGN529, in adult patients with relapsed or refractory non-Hodgkin lymphoma (NHL).
First Author: Anastasios Stathis